Seagen, Inc. (SGEN)
|Net Income (ttm)||-739.80M|
|Day's Range||164.81 - 176.03|
|52-Week Range||105.43 - 192.79|
|Price Target||186.95 (+9.9%)|
|Earnings Date||Jul 28, 2022|
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast... [Read more...]
Financial PerformanceFinancial Statements
According to 30 analysts, the average rating for SGEN stock is "Buy." The 12-month stock price forecast is 186.95, which is an increase of 9.88% from the latest price.
Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming. The post Does Merck Finally Have The Fodder It Needs To Buy Seagen?
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) relating to the parties' 200...
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.
Seagen reported second quarter revenue of $498 million, up 28%, beating analyst expectations.
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seagen reported a narrower-than-expected second-quarter loss and strong sales. But SGEN stock was unmoved in late action.
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TU...
Seattle area biotech company Seagen released early data on a trial of its drug Padcev combined with Merck's Keytruda in patients with certain types of urothelial cancer.
Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday. The post Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Wo...
Shares of Seagen Inc. SGEN, +0.71% gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in comb...
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembroliz...
– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash. , July 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembroliz...
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from...
Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entere...
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Merck & Co.'s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant's earnings later this month, though the talks remain on track, according to people fa...
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial mar...
The direction of M&A in biotech is very, very vast, says Oppenheimer's Holz
Jared Holz, Oppenheimer healthcare equity strategist, joins 'Power Lunch' to discuss the possibility of M&A in the healthcare sector, if investors remain focused on the oncology side of healthcare busin...
A new Wall Street Journal report revealed that Merck is in “advanced talks” to acquire Seattle-area biotech giant Seagen in a deal that could be worth $40 billion or more.
Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.
Shares of Seagen Inc (NASDAQ: SGEN) are up 3.0% this morning on a report that Merck & Co Inc (NYSE: MRK) is in advanced talks to buy the cancer drug specialist for at least $40 billion. Dr Gottlieb reac...